Cell Therapy News

Frederick L. Locke, MD, has been awarded a clinical research grant by The Leukemia & Lymphoma Society in collaboration with Moffitt Cancer Center.

The development of chimeric antigen receptor T cells has provided hope for patients with hematologic malignancies, but their commercial use has been limited to an option of last resort.

The FDA cleared an investigational new drug application for ALLO-605, a chimeric antigen receptor T-cell therapy for adults with relapsed or refractory multiple myeloma, according to the agent’s manufacturer.

The Leukemia & Lymphoma Society’s therapy acceleration program announced five investments intended to hasten development of immunotherapies to treat blood cancers.

Six early-career investigators received NCCN Foundation Young Investigator Awards.

The FDA granted regenerative medicine advanced therapy designation to ALLO-715, an allogeneic chimeric antigen receptor T-cell therapy for adults with relapsed or refractory multiple myeloma, according to the manufacturer.

More than half of patients with heavily pretreated melanoma responded to therapy with unselected tumor-infiltrating lymphocytes, according to results of a retrospective study.

A combination of lenzilumab and axicabtagene ciloleucel induced an 83% overall response rate among patients with advanced diffuse large B-cell lymphoma, according to topline data released by the agent’s manufacturer.

Three of four patients who received an investigational chimeric antigen receptor T-cell therapy for diffuse midline glioma showed tumor regression and improvement in neurologic symptoms, according to early results of a phase 1 study.

An FDA advisory committee concluded that the investigational cell therapy donislecel demonstrated a favorable risk-benefit profile for certain patients with difficult-to-control type 1 diabetes.